BusinessData From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian CancerBy Nasdaq OMXMar 26, 2018, 8:00 PM UTC
BusinessTesaro Announces Presentation of Niraparib Phase 3 ENGOT-OV16/NOVA Trial Secondary Endpoint Results During SGOBy Nasdaq OMXMar 13, 2017, 3:10 PM UTC
